Sort
39,280 grants matching “leukemia”
Occupational Exposure Assessment
$496,359Melissa Friesen · Division Of Cancer Epidemiology And Genetics · ZIA · FY2014 · CA
PROJECT 4: VULNERABILITY TO WHITE MATTER PROGRESSION IN SCHIZOPHRENIA
$496,303Martha Shenton · Beth Israel Deaconess Medical Center · P50 · FY2009 · MH
Fanconi Anemia: Molecular pathogenesis of Bone Marrow Failure and Clonal Evolutio
$496,270Grover Carlton Bagby · Oregon Health & Science University · P01 · FY2010 · HL
DRUG METABOLISM IN CHILDHOOD CANCER
$496,196St. Jude Children'S Research Hospital · R37 · FY2004 · CA
Cell-targeted glutamine antagonists as a novel therapy for lymphoma
$496,172Barbara Stauch Slusher · Johns Hopkins University · R01 · FY2021 · CA
Reprogramming committed blood cells to a hematopoietic stem cell fate
$496,111Derrick J. Rossi · Boston Children'S Hospital · R01 · FY2015 · HL
The pathophysiology of type 1 versus type 2 mutant calreticulin-drivenmyeloproliferative neoplasms
$496,110Shannon Elisabeth Elf · University Of Chicago · R01 · FY2022 · HL
Metabolic approaches to treat severe viral and inflammatory diseases
$496,085Augusto C Ochoa · Lsu Health Sciences Center · R01 · FY2014 · AI
Biological Breast Cancer Classification by qRT-PCR
$496,022Matthew J Ellis · Washington University · U01 · FY2009 · CA
Anticancer Agent Pharmacodynamics in Acute Leukemia
$496,004St. Jude Children'S Research Hospital · R01 · FY2005 · CA
In vivo therapy and mechanisms of PAX8-PPARgamma thyroid cancer
$495,972Ronald Jay Koenig · University Of Michigan At Ann Arbor · R01 · FY2015 · CA
In vivo therapy and mechanisms of PAX8-PPARgamma thyroid cancer
$495,972Ronald Jay Koenig · University Of Michigan At Ann Arbor · R01 · FY2016 · CA
Molecular mechanism that suppresses the proliferation of cells with supernumerary centrioles
$495,933Andrew Jon Holland · Johns Hopkins University · R01 · FY2020 · GM
Glia maturation factor-gamma modulation of signaling pathways in macrophages
$495,927Griffin Rodgers · National Heart, Lung, And Blood Institute · ZIA · FY2018 · HL
Real-World Molecularly Targeted Treatment Registry (MaTTeR): a Pilot Study to Enrich CCDI Data Utilizing Directed Electronic Medical Record (EMR) Extraction
$495,880Laurie H Glimcher · Dana-Farber Cancer Inst · P30 · FY2023 · CA
Regulation of the Fanconi Anemia Pathway by Ubiquitination
$495,880Alan David D'andrea · Dana-Farber Cancer Inst · R01 · FY2013 · DK
3H-pyrazolo[4,3-f]quinoline-containing compounds as selective and tunable protein kinase inhibitors
$495,845Herman O Sintim · Purdue University · R01 · FY2022 · CA
Targeting T-cell costimulation and cytokine activation to prevent GVHD and preserve GVL
$495,781Brian C Betts · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2016 · HL
Targeting T-cell costimulation and cytokine activation to prevent GVHD and preserve GVL
$495,781Brian C Betts · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2017 · HL
Cancer and Leukemia Group B
$495,751Harold J. Burstein · Dana-Farber Cancer Inst · U10 · FY2012 · CA
Animal Models of Polycythemia Vera
$495,722Jerry L Spivak · Icahn School Of Medicine At Mount Sinai · P01 · FY2011 · CA
Deciphering pathogenesis and therapeutic vulnerabilities in germline RUNX1 mutated AML
$495,715Wenbin Xiao · Sloan-Kettering Inst Can Research · R37 · FY2025 · CA
The role of Pleckstrin-2 as a functional node in myeloid proliferation
$495,698Peng Ji · Northwestern University At Chicago · R01 · FY2020 · HL
Targeting MicroRNAs to Eradicate Leukemia Stem Cells
$495,641Ya-Huei Kuo · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Targeting ABL kinases to regulate epithelial cell plasticity and regeneration following injury
$495,628Ann Marie Pendergast · Duke University · R01 · FY2023 · HL